本帖最后由 maicon08 于 2023-4-28 15:12 编辑
+ \& Z* v8 H9 h* r
$ i8 w4 \' L, l$ c( r; V一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，致力于癌症的预防、治疗和改善患者管理，以展示肿瘤的基础研究和临床最新研究为特点，讨论当前国际先进的治疗方法。随着中国临床研究在肿瘤领域的快速成长，中国在世界肿瘤领域中也发挥着日益重要的作用。此次会议上，中国大陆研究Oral Abstract Session入选16项，另外Clinical Science Symposium和Rapid Abstract Session部分各有1项中国研究入选，共18项。& Y: A. i2 M: S+ M% x
1 a i2 |$ {- o9 W$ v
https://www.163.com/dy/article/I3BTTPRD053438SI.html& S$ X$ ~1 a# f4 M0 A& `6 j
- w- m2 S) y+ U& N
" j* D* Q6 e4 r/ w; N) m在研疗法-免疫治疗1 [# x7 \; `2 p1 e) d# [
Developmental Therapeutics—Immunotherapy1 j& e6 z1 r8 z% S7 Y; u
- Z( N* \$ p: g% I5 x: J5 Y
摘要号：2507 标题：Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors. 报告人：丰恺超 单位：JFJ总医院第一医学中心
! G k' D5 J- [+ Q3 ?
在研疗法-分子靶向药物和肿瘤生物学 O2 A+ ^. y1 w. F, F$ S3 c( z
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
; F1 p) Q6 d: |' |4 ^ K1 e摘要号：3001 标题：BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study. 报告人：张力 单位：中山大学肿瘤防治中心
8 E" r3 s, e# ^; q
摘要号：3007 标题：A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors. 报告人：周清 单位：广东省人民医院
O8 L3 p+ l4 ?/ D% w
胃肠道肿瘤-结直肠癌和肛门癌: Q& T# c! [! i* r' R0 g
Gastrointestinal Cancer—Colorectal and Anal 摘要号：3505 标题：Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial. 报告人：张剑威 单位：中山大学附属第六医院 & k" u0 C. N# M2 c6 o. a8 Z5 z
胃肠道肿瘤-胃食管癌、胰腺癌和肝胆癌 Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary ; Y4 h* e U% h: U, F
摘要号：4001 标题：Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial. 报告人：袁庶强 单位：中山大学肿瘤防治中心
8 u* Q5 x& I8 G `, ^- y8 ~
妇科肿瘤 Gynecologic Cancer
( E1 `6 g- o1 c! {摘要号：5516 标题：Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial. 报告人：田文娟 单位：复旦大学附属肿瘤医院 ! I. ?* ^: o/ l3 D8 f
头颈肿瘤
# @* y1 z& Z, I# x( ]9 @1 ?$ z, I Head and Neck Cancer & d% n* o8 o! D( d! E+ N7 J
摘要号：6000 标题：Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial. 报告人：唐林泉 单位：中山大学肿瘤防治中心
. |5 h# W4 ~* `% A, f
摘要号：6001 标题：Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial. 报告人：陈明远 单位：中山大学肿瘤防治中心 5 W* y! Q5 ]; [3 l" s
摘要号：LBA6002 标题：PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM). 报告人：马骏 单位：中山大学肿瘤防治中心
4 v7 D6 V0 G; f r
血液系统恶性肿瘤-淋巴瘤和慢性淋巴细胞白血病 Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
; b( o) @" j" M: F) d摘要号：7503 标题：Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8). 报告人：蔡清清 单位：中山大学肿瘤防治中心
! [; G6 w) Y4 K6 k
血液系统恶性肿瘤-浆细胞疾病
2 r' R1 I$ K0 J7 ~$ h Hematologic Malignancies—Plasma Cell Dyscrasia ; N t$ g, F9 o/ K
摘要号：8005 标题：Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). 报告人：杜鹃 单位：上海长征医院
% l, g- O- Z5 r! }) g# S
肺癌-非小细胞局部-区域性/小细胞/其他胸部肿瘤7 o2 V. T# L( s3 t* |$ w2 ^
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers 6 J5 |- k/ ?4 T- H0 t: ]5 V
摘要号：8501 标题：Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study. 报告人：陆舜 单位：上海交通大学医学院附属胸科医院
U: H4 f$ L& N6 o6 V* z
肺癌-转移性非小细胞肺癌8 v4 F& L* T8 n) g+ E# Z
Lung Cancer—Non-Small Cell Metastatic 5 f6 @! O1 l7 |
摘要号：9001 标题：Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis. 报告人：吴一龙 单位：广东省人民医院 7 b7 o9 d& O( Q/ }+ V
7 i: n7 O! ^5 C5 \7 y& M摘要号：9002 标题：Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results. 报告人：王孟昭 单位：北京协和医院 3 ~7 M$ x* }# Q
摘要号：9003 标题：Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations. 报告人：邬麟 单位：湖南省肿瘤医院 }5 K4 P6 Q( }9 R& c
黑色素瘤/皮肤癌6 d+ l! G2 K' t N' B
Melanoma/Skin Cancers 摘要号：9508 标题：Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma. 报告人：郭军 单位：北京大学肿瘤医院
5 M1 Q0 @- X$ Y* p l
快速摘要报告4 F, [% ]( A9 H; E! k: E
Rapid Abstract Session 摘要号：LBA1013 标题：TORCHLIGHT: a randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC). 报告人：江泽飞 单位：JFJ总医院第五医学中心
* ]* ~) W) d, X2 }; N
临床科学研讨会
, q4 a$ x9 k! {4 {/ \9 k Clinical Science Symposium 摘要号：11510 标题：The clinical value of tumor-informed minimal residual disease detection in sarcoma. 报告人：尹军强 单位：中山大学附属第一医院
3 Q9 k- t/ h. f$ V2 O* Z) [) Q
! Z& X* Z- }: c0 Y | 
发表于 2023-4-28 14:46:30
楼主
发表于 2023-4-28 14:53:34
发表于 2023-4-28 20:42:18
，中肿在保持鼻咽癌和食道癌这些优势的同时，头颈癌和血癌也逐渐发力了
